The goal of this clinical research study is to find out if ofatumumab can control Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
This study is not yet open for participant recruitment.
Verified by M.D. Anderson Cancer Center, December 2010

First Received: December 9, 2010 Last Updated: December 10, 2010

301 Moved Permanently

(clinicaltrials.gov)